09:00

Registration and Coffee

09:25

Welcome and Introductory Remarks
Professor Andrew Elder, President, Royal College of Physicians of Edinburgh

09:30

Obesity: shared responsibility  
Professor Sir Gregor Smith, Chief Medical Officer, Scottish Government, Edinburgh
*childhood/adult global obesity statistics * impact of poor nutrition/UPF * impact of social deprivation
* value of social prescribing * benefits of exercise 

10.10

Medical management of obesity and metabolic dysfunction-associated steatotic liver disease (MASLD)  
Professor Paul Kwo, Professor of Medicine, Stanford University & Director of Hepatology, Stanford University, USA
*lifestyle modification food choices/microbiome * exercise * drugs GLP1 - role of routine continuous glucose 

10.40

Endoscopic and surgical management of obesity: will medications replace the need for these approaches?
Professor Reem Z. Sharaiha, Associate Professor of Medicine, Weill Cornell, New York, USA
*patient selection * endoscopy / surgery * complications of obesity surgery

11.15

Break

11.40

Targeting the microbiome from a gastroenterologist’s perspective
Professor Ronald Hsu, Clinical Professor of Medicine, University of California, Davis School of Medicine & Governor for Northern California, American College of Gastroenterology, USA
* repopulating the gut microbiome * National registries * faecal microbiota transplantation (FMT) patient perspective

12.15

SIR STANLEY DAVIDSON LECTURE
Chair: Professor Andrew Elder, President, Royal College of Physicians of Edinburgh

The era of disease modification in inflammatory bowel disease has arrived
Professor David T. Rubin, Professor of Medicine, University of Chicago, The Joseph B Kirsner Professor of Medicine, University of Chicago & Chief, Section of Gastroenterology, Hepatology and Nutrition, Chicago, USA
* global burden of IBD * altering the natural history * redefining treatment goals  * disease monitoring  

13.00

Lunch

13.45

Diagnosis and management of alcohol-associated liver disease
Dr Freya Rhodes, Consultant Transplant Hepatologist, Edinburgh, UK
* minimum pricing  * addiction/toxicity * 0.0% alternatives , epidemiology, diagnosis, therapies for alcohol use disorder and alcoholic hepatitis, when to consider transplant

14.20

Viral hepatitis: an endangered species 
Professor Ghias Un Nabi Tayyab, President, Pakistan Society of Gastroenterology, Pakistan
* viral hepatitis elimination models * thresholds for suppressing viral load in hepatitis B * public health/ harm reduction models

14.55

Hepatocellular carcinoma
Professor Helen Reeves, Professor of Liver Cancer & Honorary Consultant Gastroenterologist, Newcastle University, UK
* non-cirrhotic MASLD * optimal surveillance/emerging biomarkers * health economics / locoregional and systemic therapies

15.30

Break

15.50

Why quality matters in both upper and lower endoscopy
Miss Michelle Thornton, Consultant Colorectal Surgeon, NHS Scotland Academy: Endoscopy Training Co-Lead, NHS Lanarkshire, UK
* post-endoscopy upper gastrointestinal cancers (PEUGIC)/ post colonoscopy colorectal cancer (PCCRC) * optimal assessment * key performance indicators * training

16.25

DEBATE: Artificial intelligence (AI) in endoscopy will solve it all:
Against the motion: Professor Aasma Shaukat, Robert M. and Mary H. Glickman Professor of Medicine, NYU, USA

For the motion: Professor Shaji Sebastian, Consultant Physician and Gastroenterologist and Honorary Professor, Hull York Medical School, UK
* successful AI in endoscopy * clinical governance * implementation in clinical practice 

17.00

Thank you & Close